The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Silence Achieves Research Milestone Payment

28 Apr 2021 07:00

RNS Number : 7903W
Silence Therapeutics PLC
28 April 2021
 

 

Silence Therapeutics Achieves Another Research Milestone Payment from Mallinckrodt Collaboration for Complement-Mediated Diseases

 

 

28 April 2021

 

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that it has achieved another research milestone as part of its ongoing RNAi collaboration with Mallinckrodt plc ("Mallinckrodt") for complement-mediated diseases, triggering a further $2.0 million payment to Silence.

 

The milestone relates to pre-clinical development work on the SLN500 C3 targeting program, highlighting the successful ongoing collaboration between the two companies. Silence continues to work with Mallinckrodt to progress Investigational New Drug (IND) enabling studies for SLN501, the first nominated product candidate in the SLN500 program, this year.

 

The collaboration with Mallinckrodt is focused on the development and commercialization of RNAi therapeutics designed to inhibit or 'silence' the complement cascade, a group of proteins involved in the immune system and which play a role in the development of inflammation. Using Silence's proprietary mRNAi GOLD™ platform, siRNAs engineered to inhibit each target in the collaboration will be optimized and investigated before progressing into clinical development.

 

In July 2019, Silence received an upfront payment of $20 million from Mallinckrodt for an exclusive worldwide license to siRNAs against one complement target, C3, and options to license siRNAs against up to two additional targets, each of which Mallinckrodt has exercised at $2 million per target. Under the terms of the agreement, Silence is responsible for preclinical activities and for executing development of each target through Phase 1, after which Mallinckrodt will assume responsibility for clinical development and global commercialization. Silence is also eligible to receive tiered double-digit royalties on net sales for each product candidate and up to $2 billion in total milestone payments across all three targets.

 

 

 

 

Enquiries:

 

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com

 

 

Tel: +1 (646) 637-3208

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

  Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

 

About Mallinckrodt Mallinckrodt is a global business consisting of multiple wholly owned subsidiaries that develop, manufacture, market and distribute specialty pharmaceutical products and therapies. The company's Specialty Brands reportable segment's areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and gastrointestinal products. Its Specialty Generics reportable segment includes specialty generic drugs and active pharmaceutical ingredients. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements, including with respect to the Company's clinical and commercial prospects. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEFESWEFSESL
Date   Source Headline
17th Feb 20217:00 amRNSFirst dosing for SLN360
15th Feb 20213:55 pmRNSHolding(s) in Company
15th Feb 20211:14 pmRNSHolding(s) in Company
12th Feb 20214:57 pmRNSHolding(s) in Company
12th Feb 20214:53 pmRNSHolding(s) in Company
12th Feb 202112:10 pmRNSAdditional Listing and Total Voting Rights
11th Feb 20215:29 pmRNSHolding(s) in Company
11th Feb 202111:06 amRNSHolding(s) in Company
8th Feb 20214:28 pmRNSAdditional listing and Total Voting Rights
5th Feb 20217:00 amRNSSilence Announces $45m Private Placement
29th Jan 20212:35 pmRNSAdditional listing and Total Voting Rights
25th Jan 202112:41 pmRNSAdditional listing and Total Voting Rights
7th Jan 20217:00 amRNSHoldings in Company
6th Jan 202111:08 amRNSGrant of Options
6th Jan 202110:08 amRNSHolding(s) in Company
6th Jan 20217:00 amRNSBoard of Directors Appointment
6th Jan 20217:00 amRNSSilence Therapeutics Appoints Craig Tooman as CFO
5th Jan 20217:00 amRNSJanuary Conference Schedule
4th Jan 202111:45 amRNSHoldings in Company
15th Dec 202012:28 pmRNSHolding(s) in Company
4th Dec 20205:08 pmRNSAdditional listing and Total Voting Rights
3rd Dec 20209:45 amRNSDirector/PDMR Shareholding
3rd Dec 20209:44 amRNSDirector/PDMR Shareholding
17th Nov 20203:44 pmRNSAdditional listing and Total Voting Rights
16th Nov 20207:00 amRNSPositive pre-clinical data presented
2nd Nov 20207:00 amRNSSilence Therapeutics Appoints Dr. Marie Wikström
29th Oct 20204:41 pmRNSSecond Price Monitoring Extn
29th Oct 20204:36 pmRNSPrice Monitoring Extension
16th Oct 20202:05 pmRNSDirector/PDMR Shareholding
14th Oct 20201:15 pmRNSAdditional listing and Total Voting Rights
12th Oct 20203:49 pmRNSDirector/PDMR Shareholding
8th Oct 20207:00 amRNSChange to Executive Leadership Team
6th Oct 20204:25 pmRNSAdditional Listing and Total Voting Rights
1st Oct 20207:00 amRNSConference Participation
23rd Sep 20208:59 amRNSHolding(s) in Company
23rd Sep 20207:06 amRNSSecond Price Monitoring Extn
23rd Sep 20207:04 amRNSPrice Monitoring Extension
22nd Sep 20204:40 pmRNSSecond Price Monitoring Extn
22nd Sep 20204:35 pmRNSPrice Monitoring Extension
14th Sep 20207:05 amRNSGrant of options
14th Sep 20207:00 amRNSSilence Therapeutics announces new CEO
14th Sep 20207:00 amRNS2020 interim results
8th Sep 20207:01 amRNSR&D update
8th Sep 20207:00 amRNSInstructions exchanging ordinary shares for ADSs
8th Sep 20207:00 amRNSCompletion of Nasdaq listing
7th Sep 20205:47 pmRNSHolding(s) in Company
4th Sep 20202:18 pmRNSHolding(s) in Company
3rd Sep 20207:00 amRNSSilence to Participate in US Investor Conferences
1st Sep 20207:00 amRNSSilence Therapeutics Notice of Results
21st Aug 20207:00 amRNSSilence Therapeutics Files Registration with SEC

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.